Guide · Evidence
Do menopause supplements work? What the trials actually show
What placebo-controlled trials show for black cohosh, soy, ERr 731, pollen extract, S-equol and more, who funded them, and what The Menopause Society recommends.
Last updated · By the Solynes editorial team · Methodology
Short answer: A few ingredients show modest effects in some trials, but the best independent trials mostly find no clear benefit over placebo, and The Menopause Society's 2023 position statement recommends no dietary supplement for hot flashes. Soy isoflavones have the most consistent data (about 20% fewer hot flashes than placebo in one meta-analysis). Most branded ingredients rest on small trials paid for by the companies that sell them.
The evidence, ingredient by ingredient
Grades: A strong · B moderate · C limited · D none or negative (see how we grade).
| Ingredient | Grade | Trials | What reviews conclude | Menopause Society 2023 |
|---|---|---|---|---|
| Soy isoflavones & genistein | B- | dozens (Cochrane 2013 phytoestrogens: 43 RCTs; Taku 2012: 17 in MA) | Taku 2012: -20.6% frequency, -26.2% severity vs placebo; Franco JAMA 2016: -0.79 hot flashes/day; Cochrane 2013: no conclusive evidence, possible benefit at >30 mg genistein; NCCIH: effect may be small. | Not recommended (Level II) – mixed evidence. |
| Red clover | C+ | ~9 placebo RCTs (Jiang 2026 GRADE MA) | Cochrane 2013: Promensil no significant effect; Gartoulla 2014: benefit at 3–4 mo, not 12 mo; Kanadys 2021: -1.73/day; Jiang 2026: SMD -0.45. Geller 2009 12-mo RCT null. | Not specifically named (supplements not recommended). |
| Black cohosh | C | ≥16 RCTs in Cochrane 2012; 22 articles in Sadahiro 2023 MA | Cochrane 2012 (16 RCTs, 2,027 women): no difference vs placebo for hot-flush frequency. Sadahiro 2023 MA: small-moderate benefit (g 0.32 hot flashes). Manufacturer-affiliated iCR MA (2021): positive, dose-dependent. Large independent US trials (HALT 2006, Geller 2009, Pockaj 2006) null. IMS 2026 review: moderate certainty for benefit. | Not recommended (Level I) – 'insufficient evidence to support use for VMS'. |
| ERr 731 rhapontic rhubarb | C | 3 placebo RCTs by one research group (Heger 2006 n=109; Kaszkin-Bettag 2009 n=112; + earlier anxiety analysis) + Indian open-label | Dubey 2024 MA (4 studies, 390 women; industry-affiliated authors): MRS -15 points vs control. | Not recommended (Level II) – placebo-arm retention only 12.7% in key RCT; open-label study. |
| Flower pollen extract | C | 2 small placebo RCTs (Winther 2005 n=64; Bounous 2024 n=39 breast-cancer survivors) + observational | Acquarulo 2024 MA (1 RCT + 4 observational, n=420): big before/after changes, but pooled controlled data NOT significant – possibly placebo. | Not recommended (Level III). |
| S-equol | C | ~5–6 RCTs (Daily 2019 MA: 6 studies, 779 women) | Daily 2019 MA: benefit on hot-flash scores, 3/5 trials positive, 2 null; most trials <50/group. | Not recommended (Level II) – mixed evidence. |
| EstroG-100 | C | 3 placebo RCTs (Chang 2012 n=64; Farzaneh 2024 n=120/70 analyzed; Snigdha 2025 n=80 combo with GABA) | No independent meta-analysis found. | Not specifically assessed (falls under 'supplements/herbal remedies – not recommended'). |
| Ammonium succinate (Amberen) | C | 2 identical placebo RCTs (pooled n=227) + 1 open-label combo study (n=106) | Only manufacturer-linked pooled analysis (2019). | Not recommended (Level II) – limited, manufacturer-sponsored. |
| Pycnogenol (pine bark) | C | 3 placebo/controlled RCTs (n=170, ~200, 38) | Cochrane 2020 (pine bark, chronic disorders) did not include menopause and found low-quality evidence overall. | Not assessed. |
| Fenugreek | C | ≥3 placebo RCTs (n=115, 88, 138+ with shatavari) | No MA located. | Not assessed. |
| Sage | C | ~4 placebo RCTs (310 women, Moradi 2023) + open-label | Moradi 2023: frequency effect not significant overall. | Not assessed. |
| Hops (8-PN) | C- | 3–4 small RCTs (n=36–120) + soy-hop combo | No MA located. | Not assessed. |
| Evening primrose oil | D | ~6 RCTs (Larki 2025 MA, 450 women) | Thevi 2024 & Larki 2025: no significant reduction in frequency; possible small severity effect. | Not recommended (Level II). |
| Omega-3 (fish oil) | D | 2 key RCTs (Lucas 2009 n=120; Cohen 2014 n=355) | Iqbal 2023 SR: no substantial evidence for VMS, sleep or depression. | Not recommended (Level III) – mixed. |
| Magnesium | D | 1 large RCT (Park 2015, n=289) | Null for hot flashes. | Not assessed. |
Why placebo matters so much
Hot flashes improve a lot on placebo. In an NIH-funded 12-month trial (Geller 2009), hot flashes fell 63% on placebo, 34% on black cohosh and 57% on red clover, versus 94% on hormone therapy. Neither botanical beat placebo. The NIH-funded HALT study (Newton 2006) found no herbal arm differed from placebo by even one hot flash a day, while hormone therapy reduced about four a day.
That is why before-and-after results (“73% fewer hot flashes”) say little on their own. For pollen extract, a 2024 meta-analysis (Acquarulo 2024) found large before-and-after changes, but when only controlled studies were pooled, the effect was not statistically significant.
Who pays for the research
By our reading of the funding statements in our 79-entry study library, 19 are linked to a manufacturer or ingredient supplier and 34 are independent or academic; 25 do not state funding in the abstract. Examples: the main S-equol trials were funded by Otsuka and Pharmavite; the EstroG-100 + GABA trial behind OLLY Mellow Menopause was run by OLLY employees (Snigdha 2025); the Amberen trials are manufacturer-linked (Radzinsky 2019).
Where the evidence is most promising
- Soy isoflavones & genistein: Taku 2012: -20.6% frequency, -26.2% severity vs placebo; Franco JAMA 2016: -0.79 hot flashes/day; Cochrane 2013: no conclusive evidence, possible benefit at >30 mg genistein; NCCIH: effect may be small.
- Black cohosh: the Remifemin (iCR) extract has positive manufacturer-linked trials, such as Osmers 2005 (304 women), but the independent Cochrane review (Leach 2012) found no difference from placebo.
- ERr 731 rhapontic rhubarb: two placebo-controlled trials in perimenopausal women reported large improvements (Heger 2006, Kaszkin-Bettag 2009), both from one research group.
Where it isn't
- Evening primrose oil, Omega-3 (fish oil) and Magnesium: trials found no effect on how often hot flashes happen.
- DIM: no menopause-symptom trial at all.
- Sage: a 2023 meta-analysis found no significant effect on frequency.
What does have evidence
The Menopause Society's 2023 nonhormone statement lists CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III). Hormone therapy is also an option for many women. These are prescribed or delivered by clinicians, so the most useful next step for bothersome symptoms is a conversation with one. Read the statement (PDF).
If you still want to try a supplement
- Choose an ingredient at the dose used in trials (check each product's label on its page).
- Prefer products listed in a public testing registry (see NSF-certified options).
- Give it a defined trial period and track symptoms, since placebo effects are large.
- Tell your clinician and pharmacist, especially if you take medication.
FAQ
Is there any menopause supplement proven to work?
No supplement has strong (grade A) evidence for hot flashes, and The Menopause Society (2023) recommends none. Soy isoflavones show a modest average effect in meta-analyses (grade B-).
What works better than supplements for hot flashes?
The Menopause Society lists hormone therapy and non-hormonal options with evidence: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III). Ask a clinician which fits you.
More guides
- Black cohosh: what the studies show, liver safety and adulterationNov 19, 2026
- Estroven vs Amberen vs Relizen vs Remifemin: an evidence-based comparisonNov 19, 2026
- Menopause supplements with NSF certification, checked against the registryNov 19, 2026
- Menopause supplements for hot flashes, sleep and mood: what's been studied for eachNov 19, 2026
- Soy isoflavones and breast cancer: what's known (and what isn't)Nov 19, 2026
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.